NCT00734032View on ClinicalTrials.gov

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

August 26, 2008

Primary Completion Date

January 16, 2009

Study Completion Date

January 16, 2009

Conditions
Atherosclerosis
Interventions
DRUG

SB480848 40mg EC Tablet

1 tablet once a day

DRUG

SB480848 80mg EC Tablet

1 tablet once a day

DRUG

SB480848 160mg EC Tablet

1 tablet once a day

DRUG

SB480848 Placebo Tablet

1 tablet once a day

Trial Locations (7)

812-0025

GSK Investigational Site, Fukuoka

818-0036

GSK Investigational Site, Fukuoka

819-1102

GSK Investigational Site, Fukuoka

105-0004

GSK Investigational Site, Tokyo

154-0024

GSK Investigational Site, Tokyo

160-0017

GSK Investigational Site, Tokyo

174-0051

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00734032 - A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients | Biotech Hunter | Biotech Hunter